These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24050826

  • 1. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A, Salazar-Sánchez L.
    Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
    [Abstract] [Full Text] [Related]

  • 2. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.
    Circulation; 2004 Jul 27; 110(4):392-8. PubMed ID: 15249498
    [Abstract] [Full Text] [Related]

  • 3. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C, Omran H, Tripp C, Poetzsch B.
    Thromb Haemost; 2009 Feb 27; 101(2):325-32. PubMed ID: 19190817
    [Abstract] [Full Text] [Related]

  • 4. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
    Moten MA, Gaber AO, Putney D, Patel SJ.
    Clin Transplant; 2013 Feb 27; 27(6):852-7. PubMed ID: 24033530
    [Abstract] [Full Text] [Related]

  • 5. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.
    G Ital Nefrol; 2010 Feb 27; 27(6):649-54. PubMed ID: 21132647
    [Abstract] [Full Text] [Related]

  • 6. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR.
    J Crit Care; 2011 Aug 27; 26(4):347-51. PubMed ID: 21454037
    [Abstract] [Full Text] [Related]

  • 7. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A, Held K, Oschman A.
    Pediatr Blood Cancer; 2014 Jun 27; 61(6):1063-7. PubMed ID: 24375987
    [Abstract] [Full Text] [Related]

  • 8. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW, Lee JJ.
    Am Heart J; 2004 Oct 27; 148(4):582-9. PubMed ID: 15459586
    [Abstract] [Full Text] [Related]

  • 9. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT.
    Ann Pharmacother; 2004 Apr 27; 38(4):563-8. PubMed ID: 14982983
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.
    Crit Care Med; 2003 May 27; 31(5):1405-9. PubMed ID: 12771610
    [Abstract] [Full Text] [Related]

  • 13. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM.
    Am Heart J; 2001 Oct 27; 142(4):590-3. PubMed ID: 11579347
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Low-molecular-weight heparin in patients with advanced cirrhosis.
    Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P.
    Liver Int; 2011 Jan 27; 31(1):75-82. PubMed ID: 20958919
    [Abstract] [Full Text] [Related]

  • 16. Enoxaparin in acute coronary syndromes.
    Lee S, Gibson CM.
    Expert Rev Cardiovasc Ther; 2007 May 27; 5(3):387-99. PubMed ID: 17489664
    [Abstract] [Full Text] [Related]

  • 17. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
    Kopelman TR, O'Neill PJ, Pieri PG, Salomone JP, Hall ST, Quan A, Wells JR, Pressman MS.
    Am J Surg; 2013 Dec 27; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G.
    Kidney Blood Press Res; 2004 Dec 27; 27(4):211-7. PubMed ID: 15273423
    [Abstract] [Full Text] [Related]

  • 19. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP.
    Thromb Res; 2009 Apr 27; 123(6):845-7. PubMed ID: 19038418
    [Abstract] [Full Text] [Related]

  • 20. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
    Hiscock RJ, Casey E, Simmons SW, Walker SP, Newell PA.
    Int J Obstet Anesth; 2013 Nov 27; 22(4):280-8. PubMed ID: 23958275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.